Mr. Thomas Arthur Small, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 132 Laceleaf Ln, Cibolo, TX 78108 Phone: 210-945-4972 |
Mr. Anthony Christian Terry, CSFA Physician Assistant - Surgical Medicare: Not Enrolled in Medicare Practice Location: 725 Fm 1103 Unit 386, Cibolo, TX 78108 Phone: 210-279-8634 |
Courtney Michelle Talka, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 124 Grassland Dr, Cibolo, TX 78108 Phone: 915-201-9915 |
Mr. Jeffrey L. Scott, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 791 Fm 1103, Suite # 125, Cibolo, TX 78108 Phone: 210-888-1175 |
Trina Denise St Ann, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 791 Fm 1103 Ste 125, Cibolo, TX 78108 Phone: 218-888-1175 Fax: 210-888-0042 |
News Archive
Scientists from Brigham and Women's Hospital and Dana-Farber Cancer Institute and their colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.
Today, in what has been the culmination of more than two decades of research and advocacy, the United States Preventive Services Task Force issued its final recommendation approving CT screening for those at high risk for lung cancer. The recommendation sets the stage for both public and private insurance coverage and is expected to bring about a dramatic increase in lung cancer survival.
Today is the shortest day of the year. During the dark winter months, sunlight can be an insufficient source of vitamin D which is vital for the absorption of calcium and phosphorous. Low vitamin D levels have recently been linked to a greater chance of developing diseases including diabetes and heart disease, several cancers and the common cold.
At the start of reproductive life an ovary contains, on average, several thousands of immature ovules in a resting state that can last for several decades.
TESARO, Inc. announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).
› Verified 8 days ago